Comprehensive mapping of cell fates in microsatellite unstable cancer cells supports dual targeting of WRN and ATR

• Published in: Genes & development 2023-10, Vol.37 (19-20), p.913-928
• Main Authors: Zong, Dali, Koussa, Natasha C, Cornwell, James A, Pankajam, Ajith V, Kruhlak, Michael J, Wong, Nancy, Chari, Raj, Cappell, Steven D, Nussenzweig, André
• Format: Article
• Language: English
• Subjects: Ataxia Telangiectasia Mutated Proteins - genetics; Ataxia Telangiectasia Mutated Proteins - metabolism; DNA Damage; DNA Helicases - metabolism; DNA Replication - genetics; Exodeoxyribonucleases - genetics; Exodeoxyribonucleases - metabolism; Humans; Microsatellite Repeats; Neoplasms - drug therapy; Neoplasms - genetics; RecQ Helicases - genetics; RecQ Helicases - metabolism; Research Papers; Werner Syndrome Helicase - genetics; Werner Syndrome Helicase - metabolism
• ISSN: 0890-9369; 1549-5477
• DOI: 10.1101/gad.351085.123

Addiction to the WRN helicase is a unique vulnerability of human cancers with high levels of microsatellite instability (MSI-H). However, while prolonged loss of WRN ultimately leads to cell death, little is known about how MSI-H cancers initially respond to acute loss of WRN-knowledge that would be helpful for informing clinical development of WRN targeting therapy, predicting possible resistance mechanisms, and identifying useful biomarkers of successful WRN inhibition. Here, we report the construction of an inducible ligand-mediated degradation system in which the stability of endogenous WRN protein can be rapidly and specifically tuned, enabling us to track the complete sequence of cellular events elicited by acute loss of WRN function. We found that WRN degradation leads to immediate accrual of DNA damage in a replication-dependent manner that curiously did not robustly engage checkpoint mechanisms to halt DNA synthesis. As a result, WRN-degraded MSI-H cancer cells accumulate DNA damage across multiple replicative cycles and undergo successive rounds of increasingly aberrant mitoses, ultimately triggering cell death. Of potential therapeutic importance, we found no evidence of any generalized mechanism by which MSI-H cancers could adapt to near-complete loss of WRN. However, under conditions of partial WRN degradation, addition of low-dose ATR inhibitor significantly increased their combined efficacy to levels approaching full inactivation of WRN. Overall, our results provide the first comprehensive view of molecular events linking upstream inhibition of WRN to subsequent cell death and suggest that dual targeting of WRN and ATR might be a useful strategy for treating MSI-H cancers.